ViroPharma Incorporated Completes Acquisition of Lev Pharm... (ks. Separately ViroPharma announced t...)

ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals

Date:10/21/2008

ks.

Separately, ViroPharma announced that the U.S. Food and Drug Administration (FDA) granted seven years of marketing exclusivity to Cinryze C1 inhibitor (human) for routine prophylaxis of hereditary angioedema (HAE) pursuant to the Orphan Drug Act. Lev originally received orphan drug designation for Cinryze by the Office of Orphan Products Development on July 16, 2004.

"We are extremely excited to receive the grant of seven years of market exclusivity for Cinryze in prophylaxis against HAE, and to complete this acquisition; we now turn our attention to finalizing a robust patient access program and launching Cinryze into the HAE prophylaxis market," commented Vincent Milano, ViroPharma's president and chief executive officer. "Cinryze is not only a life-saving therapy treating a very dangerous disease, but also a product capable of significantly improving the everyday lives of patients. We are committed to the launch, and to ensuring that patients around the country suffering from this debilitating disease have access to the drug."

"We are pleased that we have completed this acquisition by ViroPharma and are confident in their commitment to ensuring that all patients who need access to Cinryze will have access to this life-saving therapy," commented Judson Cooper, Lev's former chairman of the board. "This transaction provides our stockholders with attractive financial terms, through the upfront payment and the opportunity to continue to share in the success of the drug through the ownership of ViroPharma shares and the contingent value rights."

Share exchange information and a letter of transmittal will be emailed to Lev stockholders shortly. If you have any questions, please contact ViroPharma's exchange agent, StockTrans, at (800) 733-1121.

Conference Call and Webcast Information

ViroPharma intends to discuss the approval and indication of Cinryze during its third quarter 2008 financial conference call, to be held on Wed
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6
Related medicine technology :

1. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
2. ViroPharma Announces Discontinuation of HCV-796 Development
3. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
4. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. ViroPharma to Present at the Natixis Bleichroeder Conference
6. ViroPharma to Present at Three Upcoming Healthcare Conferences
7. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
8. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
9. Genta Incorporated Announces Third Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial With Intravenous Delivery of JX-594 Oncolytic Virus

Post Your Comments:

ViroPharma Incorporated Completes Acquisition of Lev Pharm...(ks. Separately ViroPharma announced t...),Health